Novocure Limited Quick Ratio (NVCR) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Novocure Limited  (NASDAQ: NVCR)

Novocure Limited's Quick Ratio

NVCR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.45 a new company low.

Within Medical Equipment & Supplies industry 150 other companies have achieved higher Quick Ratio than Novocure Limited in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 777 to 2513.

Explain Quick Ratio?
How much Cash & cash equivalents NVCR´s has?
What are NVCR´s Current Liabilities?




NVCR Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change -66.73 % -80.55 % -81.57 % 4.76 % 635.79 %
Y / Y Cash & cash equivalent Change -89.11 % -53.5 % -53.36 % 7.67 % -4.17 %
Quick Ratio MRQ 0.45 3.4 3.66 1.52 1.37
NVCR's Total Ranking # 2513 # 777 # 392 # 1243 # 38
Seq. Current Liabilities Change 73.46 % 4.1 % -82.01 % 2.42 % 1.44 %
Seq. Cash & cash equivalent Change -77.02 % -3.5 % -56.68 % 13.38 % -1.89 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 151
Healthcare Sector # 740
Overall Market # 2513


Quick Ratio Statistics
High Average Low
16.4 7.52 0.45
(Mar 31 2021)   (Jun 30 2026)




Financial Statements
Novocure Limited's Current Liabilities $ 221 Millions Visit NVCR's Balance sheet
Novocure Limited's Cash & cash equivalent $ 99 Millions Visit NVCR's Balance sheet
Source of NVCR's Sales Visit NVCR's Sales by Geography


Cumulative Novocure Limited's Quick Ratio

NVCR's Quick Ratio for the trailling 12 Months

NVCR Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -56.27 % -22.55 % 42.58 % 189.94 % 654.4 %
Y / Y Cash & cash equivalent TTM Growth -46.48 % -25.67 % -11.21 % 3.85 % 2.94 %
Quick Ratio TTM 1.75 1.77 1.57 1.44 1.43
Total Ranking TTM # 3931 # 2932 # 2013 # 2886 # 189
Seq. Current Liabilities TTM Growth -27.8 % -24.86 % -20.34 % 1.17 % 27.88 %
Seq. Cash & cash equivalent TTM Growth -28.75 % -14.97 % -13.36 % 1.96 % -1.04 %


On the trailing twelve months basis In spite of the year on year decrease in NVCR's Current Liabilities to $220.71 millions, cumulative Quick Ratio to 1.75 below the NVCR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 199 other companies have achieved higher Quick Ratio than Novocure Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2932 to 3931.

Explain Quick Ratio?
How much Cash & cash equivalents NVCR´s has?
What are NVCR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 200
Healthcare Sector # 887
Within the Market # 3931


trailing twelve months Quick Ratio Statistics
High Average Low
7.61 4.61 1.26
(Sep 30 2021)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Lucid Diagnostics Inc   1.21 $ 33.404  Millions$ 27.516  Millions
Sintx Technologies Inc   1.21 $ 3.590  Millions$ 2.977  Millions
Vaso Corporation  1.17 $ 38.291  Millions$ 32.863  Millions
Koru Medical Systems Inc   1.15 $ 8.288  Millions$ 7.180  Millions
Establishment Labs Holdings Inc   1.10 $ 71.157  Millions$ 64.558  Millions
Treace Medical Concepts Inc   1.10 $ 45.619  Millions$ 41.496  Millions
Resmed Inc   1.05 $ 1,469.234  Millions$ 1,395.110  Millions
Adagio Medical Holdings inc   1.02 $ 7.740  Millions$ 7.562  Millions
Plus Therapeutics Inc   1.00 $ 8.587  Millions$ 8.567  Millions
Pavmed Inc   1.00 $ 4.070  Millions$ 4.088  Millions
Sonoma Pharmaceuticals Inc   0.98 $ 5.338  Millions$ 5.447  Millions
Nuwellis Inc   0.98 $ 3.922  Millions$ 4.008  Millions
Electrocore Inc   0.97 $ 11.543  Millions$ 11.933  Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________  0.96 $ 10.924  Millions$ 11.366  Millions
Medline Inc   0.96 $ 2,677.000  Millions$ 2,803.000  Millions
Neuronetics Inc   0.88 $ 24.947  Millions$ 28.309  Millions
Orthopediatrics Corp  0.87 $ 45.879  Millions$ 52.852  Millions
Haemonetics Corporation  0.85 $ 223.384  Millions$ 263.235  Millions
Lifeward ltd   0.85 $ 9.448  Millions$ 11.159  Millions
Qhslab Inc   0.84 $ 0.317  Millions$ 0.376  Millions
Intelligent Bio Solutions Inc   0.84 $ 4.141  Millions$ 4.935  Millions
Integra Lifesciences Holdings Corp  0.83 $ 274.084  Millions$ 330.881  Millions
Lifestance Health Group Inc   0.82 $ 225.943  Millions$ 274.753  Millions
Pro dex Inc   0.81 $ 10.542  Millions$ 13.086  Millions
Carlisle Companies Incorporated  0.75 $ 665.300  Millions$ 888.400  Millions
Northview Acquisition Corp  0.73 $ 12.200  Millions$ 16.622  Millions
Livanova Plc  0.73 $ 516.619  Millions$ 707.004  Millions
Angiodynamics Inc   0.72 $ 53.864  Millions$ 74.717  Millions
Rosecliff Acquisition Corp I  0.70 $ 14.000  Millions$ 19.869  Millions
Innovage Holding Corp   0.69 $ 141.326  Millions$ 203.891  Millions

Date modified: 2026-09-08T21:20:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.